Compare
Rybrevant vs. Tagrisso

Rybrevant (amivantamab-vmjw) is an FDA approved injection used to treat adults with non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It's given as an infusion through your vein (IV), and your dosing schedule depends on the type of lung cancer being treated. You also might receive it with other cancer medications. Common side effects include infusion-related reactions, rash, tiredness, and skin infections around the nails.

Adults with advanced or metastatic NSCLC with certain EGFR mutations:

• Used with lazertinib as a first-choice treatment
• Used with carboplatin and pemetrexed if the cancer has gotten worse or it didn't respond well to EGFR inhibitors
• Used with carboplatin and pemetrexed as a first-choice treatment
• Used alone if the cancer has gotten worse or didn't respond well to platinum-based chemotherapy

Used with lazertinib:

• Rash
• Infected skin around the nail
• Muscle and joint pain
• Mouth sores
• Swelling
• Tingling sensation
• Tiredness
• Diarrhea
• Constipation
• COVID-19
• Dry skin
• Bleeding
• Reduced appetite
• Itchy skin
• Nausea
• Changes in certain blood tests

Used with carboplatin and pemetrexed:

• Rash
• Infected skin around the nail
• Tiredness
• Nausea
• Mouth sores
• Constipation
• Swelling
• Reduced appetite
• Muscle and joint pain
• Vomiting
• COVID-19
• Changes in certain blood tests

Used alone:

• Rash
• Infected skin around the nail
• Muscle and joint pain
• Shortness of breath
• Nausea
• Tiredness
• Swelling
• Mouth sores
• Cough
• Constipation
• Vomiting
• Changes in certain blood tests

• Infusion-related reactions
• Lung problems
• Blood clots (when used with lazertinib)
• Skin problems
• Eye problems
• Harm to the unborn baby

Tagrisso (osimertinib) is a prescription tablet used to treat adults with certain types of non-small-cell lung cancer (NSCLC) with a specific mutation in the EGFR gene. It’s FDA approved for use in early-stage cases after surgery, as well as in advanced and metastatic stages. This medication is an EGFR inhibitor that helps slow the growth and spread of cancer cells. It’s typically taken once a day by mouth, with or without food. Common side effects include low blood cell counts, diarrhea, and rash.

Non-small-cell lung cancer (NSCLC) in adults with specific EGFR mutations, including:

• Early-stage NSCLC after surgery to remove the tumor
• Advanced NSCLC that can’t be removed by surgery, if the cancer hasn’t gotten worse with platinum-based chemotherapy and radiation therapy
• Metastatic NSCLC as the first treatment
• Advanced or metastatic NSCLC as a first treatment taken together with pemetrexed and platinum-based chemotherapy
• Metastatic NSCLC that’s longer responding to other EGFR inhibitors

• Low white blood cell count (up to 65%)
• Low platelet count (53%)
• Low red blood cell count (52%)
• Diarrhea (47%)
• Skin rash (46%)
• Muscle pain (38%)
• Nail changes (34%)
• Dry skin (32%)
• Mouth sores (24%)
• Tiredness (21%)

• Lung problems
• Heart rhythm problem (QT prolongation)
• Heart problems
• Eye problems
• Skin problems
• Inflammation of the blood vessels in your skin
• Blood and bone marrow problems
• Harm to unborn baby